Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROX study of CT-P6 plus SOX or CapeOX for HER2-positive advanced or recurrent gastric cancer
jRCTs071190007Phase 2Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab, oxaliplatin, tegafur and capecitabine in gastric cancer (GC) (2 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Response rate. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs071190007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190007.